Skip to main content

insulin degludec (Tresiba®)

 

Status: In progress

Treatment of diabetes mellitus in adolescents and children from the age of 1 year.

Medicine details

Medicine name insulin degludec (Tresiba®)
Formulation 100 units/ml and 200 units/ml solution for injection
Reference number 5196
Indication

As above

Company Novo Nordisk Ltd
BNF chapter Endocrine system
Submission type Licence extension for paediatric use
Status In progress
AWMSG meeting date 14/09/2022
Date of issue TBA
Follow AWTTC: